Evidence map›Paper›PMID 29043454›Full record

ArticleJournal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry2017

A fluorescent oxaliplatin derivative for investigation of oxaliplatin resistance using imaging techniques.

Ganna V Kalayda, Maximilian Kullmann, Mathea Sophia Galanski, Sabrina Gollos

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ganna V KalaydaDepartment of Clinical Pharmacy, Pharma Centre Bonn, Institute of Pharmacy, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany. akalayda@uni-bonn.de.
Maximilian KullmannDepartment of Clinical Pharmacy, Pharma Centre Bonn, Institute of Pharmacy, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany.
Mathea Sophia GalanskiInstitute of Inorganic Chemistry, University of Vienna, Waehringer Str. 42, 1090, Vienna, Austria.
Sabrina GollosDepartment of Pharmaceutical Chemistry, Pharma Centre Bonn, Institute of Pharmacy, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxaliplatin is the backbone of chemotherapy for advanced colorectal cancer and undergoes clinical trials for treatment of other tumour entities. However, acquired resistance is a major hurdle. Confocal microscopy is a useful tool to get an insight into the mechanisms of resistance but it requires fluorescent compounds. This work describes the synthesis of the novel oxaliplatin derivative (CFDA-oxPt) featuring 5(6)-carboxyfluorescein diacetate and evaluation of its applicability for the investigation of oxaliplatin resistance using imaging techniques. CFDA-oxPt was somewhat less cytotoxic than oxaliplatin in sensitive colorectal cancer cells, with EC

Indexed as

Drug Resistance, NeoplasmMolecular ImagingAntineoplastic AgentsBiological TransportCell Line, TumorFluoresceinsFluorescent DyesHumansOrganoplatinum CompoundsOxaliplatin6-carboxyfluoresceinAntineoplastic AgentsFluoresceinsFluorescent DyesOrganoplatinum CompoundsOxaliplatinCellular distributionFluorescent probesLive-cell microscopyPlatinum complexes

Identifiers

PMID29043454

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.